Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$54.04K$54.04K+153.6% vs Q3 2018 Net Income-$1.41M-$1.41MN/M vs Q3 2018 EPS Diluted-$1.81-$1.81N/M vs Q3 2018 Gross Profit$45,114+165.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,016,770N/M Free Cash Flowderived-$1,017,493N/M Margins · derivedGross margin83.5%+3.7 pt vs Q3 2018
Operating margin-2389.5%+2469.3 pt vs Q3 2018
Net margin-2602.2%+25315.8 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 19, 2019 · 50 d after period end